Patents by Inventor Xiong Cai

Xiong Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20150274678
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Application
    Filed: March 5, 2015
    Publication date: October 1, 2015
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould
  • Quinazoline based EGFR inhibitors
    Patent number: 9108929
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: August 18, 2015
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
    Publication number: 20150203509
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: November 12, 2014
    Publication date: July 23, 2015
    Inventors: Xiong Cai, Haixaio Zhai, Chengjung Lai, Changgeng Qian
  • Fused amino pyridine as HSP90 inhibitors
    Patent number: 9040556
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 26, 2015
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 9024024
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: May 5, 2015
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould, Haixiao Zhai
  • Quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8975401
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 10, 2015
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould
  • FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS
    Publication number: 20150018385
    Abstract: The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
    Type: Application
    Filed: May 12, 2014
    Publication date: January 15, 2015
    Inventors: Xiong Cai, Changgeng Qian
  • Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
    Patent number: 8906909
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 9, 2014
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
  • Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8846912
    Abstract: The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below: These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and may further act as HDAC inhibitors. The invention further relates to the use of these tartrate salts in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: September 30, 2014
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
    Publication number: 20140243330
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: March 5, 2014
    Publication date: August 28, 2014
    Applicant: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
  • QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20140221403
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Application
    Filed: November 25, 2013
    Publication date: August 7, 2014
    Applicant: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould, Haixiao Zhai
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20140221343
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: October 15, 2013
    Publication date: August 7, 2014
    Applicant: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
    Publication number: 20140155595
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: May 13, 2013
    Publication date: June 5, 2014
    Applicant: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
  • QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20140155606
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
    Type: Application
    Filed: May 15, 2013
    Publication date: June 5, 2014
    Applicant: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Stephen Gould
  • Fused amino pyridines for the treatment of brain tumors
    Patent number: 8722703
    Abstract: The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: May 13, 2014
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian
  • TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20140128410
    Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 8, 2014
    Applicant: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
  • Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
    Patent number: 8710219
    Abstract: The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 29, 2014
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
  • CDK inhibitors
    Patent number: 8691820
    Abstract: The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 8, 2014
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai, Haixiao Zhai
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
    Publication number: 20140023642
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 31, 2012
    Publication date: January 23, 2014
    Applicant: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES
    Publication number: 20140018368
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 16, 2014
    Applicants: Genetech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai